189 related articles for article (PubMed ID: 15156182)
21. The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner.
Elsässer A; Franzen M; Kohlmann A; Weisser M; Schnittger S; Schoch C; Reddy VA; Burel S; Zhang DE; Ueffing M; Tenen DG; Hiddemann W; Behre G
Oncogene; 2003 Aug; 22(36):5646-57. PubMed ID: 12944913
[TBL] [Abstract][Full Text] [Related]
22. The distal zinc finger domain of AML1/MDS1/EVI1 is an oligomerization domain involved in induction of hematopoietic differentiation defects in primary cells in vitro.
Senyuk V; Li D; Zakharov A; Mikhail FM; Nucifora G
Cancer Res; 2005 Sep; 65(17):7603-11. PubMed ID: 16140925
[TBL] [Abstract][Full Text] [Related]
23. Repression of RUNX1 activity by EVI1: a new role of EVI1 in leukemogenesis.
Senyuk V; Sinha KK; Li D; Rinaldi CR; Yanamandra S; Nucifora G
Cancer Res; 2007 Jun; 67(12):5658-66. PubMed ID: 17575132
[TBL] [Abstract][Full Text] [Related]
24. The AML1/ETO(MTG8) and AML1/Evi-1 leukemia-associated chimeric oncoproteins accumulate PEBP2beta(CBFbeta) in the nucleus more efficiently than wild-type AML1.
Tanaka K; Tanaka T; Kurokawa M; Imai Y; Ogawa S; Mitani K; Yazaki Y; Hirai H
Blood; 1998 Mar; 91(5):1688-99. PubMed ID: 9473235
[TBL] [Abstract][Full Text] [Related]
25. AML-2 is a potential target for transcriptional regulation by the t(8;21) and t(12;21) fusion proteins in acute leukemia.
Meyers S; Lenny N; Sun W; Hiebert SW
Oncogene; 1996 Jul; 13(2):303-12. PubMed ID: 8710369
[TBL] [Abstract][Full Text] [Related]
26. Williams-Beuren syndrome critical region-5/non-T-cell activation linker: a novel target gene of AML1/ETO.
Fliegauf M; Stock M; Berg T; Lübbert M
Oncogene; 2004 Dec; 23(56):9070-81. PubMed ID: 15489901
[TBL] [Abstract][Full Text] [Related]
27. PRDX4, a member of the peroxiredoxin family, is fused to AML1 (RUNX1) in an acute myeloid leukemia patient with a t(X;21)(p22;q22).
Zhang Y; Emmanuel N; Kamboj G; Chen J; Shurafa M; Van Dyke DL; Wiktor A; Rowley JD
Genes Chromosomes Cancer; 2004 Aug; 40(4):365-70. PubMed ID: 15188461
[TBL] [Abstract][Full Text] [Related]
28. Overexpression of the AML1 proto-oncoprotein in NIH3T3 cells leads to neoplastic transformation depending on the DNA-binding and transactivational potencies.
Kurokawa M; Tanaka T; Tanaka K; Ogawa S; Mitani K; Yazaki Y; Hirai H
Oncogene; 1996 Feb; 12(4):883-92. PubMed ID: 8632911
[TBL] [Abstract][Full Text] [Related]
29. The corepressor CtBP interacts with Evi-1 to repress transforming growth factor beta signaling.
Izutsu K; Kurokawa M; Imai Y; Maki K; Mitani K; Hirai H
Blood; 2001 May; 97(9):2815-22. PubMed ID: 11313276
[TBL] [Abstract][Full Text] [Related]
30. Interaction and functional cooperation of the leukemia-associated factors AML1 and p300 in myeloid cell differentiation.
Kitabayashi I; Yokoyama A; Shimizu K; Ohki M
EMBO J; 1998 Jun; 17(11):2994-3004. PubMed ID: 9606182
[TBL] [Abstract][Full Text] [Related]
31. Expression and regulation of the evi-1 gene in the human factor-dependent leukemia cell line, UCSD/AML1.
Oval J; Smedsrud M; Taetle R
Leukemia; 1992 May; 6(5):446-51. PubMed ID: 1593910
[TBL] [Abstract][Full Text] [Related]
32. The role of Runx1/AML1 and Evi-1 in the regulation of hematopoietic stem cells.
Kumano K; Kurokawa M
J Cell Physiol; 2010 Feb; 222(2):282-5. PubMed ID: 19847803
[TBL] [Abstract][Full Text] [Related]
33. Inability of RUNX1/AML1 to breach AML1-ETO block of embryonic stem cell definitive hematopoiesis.
Peterson LF; Lo MC; Okumura AJ; Zhang DE
Blood Cells Mol Dis; 2007; 39(3):321-8. PubMed ID: 17692541
[TBL] [Abstract][Full Text] [Related]
34. The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B.
Frank R; Zhang J; Uchida H; Meyers S; Hiebert SW; Nimer SD
Oncogene; 1995 Dec; 11(12):2667-74. PubMed ID: 8545124
[TBL] [Abstract][Full Text] [Related]
35. A novel gene, FGA7, is fused to RUNX1/AML1 in a t(4;21)(q28;q22) in a patient with T-cell acute lymphoblastic leukemia.
Mikhail FM; Coignet L; Hatem N; Mourad ZI; Farawela HM; El Kaffash DM; Farahat N; Nucifora G
Genes Chromosomes Cancer; 2004 Feb; 39(2):110-8. PubMed ID: 14695990
[TBL] [Abstract][Full Text] [Related]
36. Rearrangement of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: expression of co-existing multiple chimeric genes with similar functions as transcriptional repressors, but with opposite tumorigenic properties.
Zent C; Kim N; Hiebert S; Zhang DE; Tenen DG; Rowley JD; Nucifora G
Curr Top Microbiol Immunol; 1996; 211():243-52. PubMed ID: 8585955
[TBL] [Abstract][Full Text] [Related]
37. Oncogenic mechanisms of Evi-1 protein.
Hirai H; Izutsu K; Kurokawa M; Mitani K
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S35-40. PubMed ID: 11587364
[TBL] [Abstract][Full Text] [Related]
38. Both AML1 and EVI1 oncogenic components are required for the cooperation of AML1/MDS1/EVI1 with BCR/ABL in the induction of acute myelogenous leukemia in mice.
Cuenco GM; Ren R
Oncogene; 2004 Jan; 23(2):569-79. PubMed ID: 14724585
[TBL] [Abstract][Full Text] [Related]
39. Leukemogenesis by the chromosomal translocations.
Mitani K
Leukemia; 1997 Apr; 11 Suppl 3():294-6. PubMed ID: 9209370
[TBL] [Abstract][Full Text] [Related]
40. RUNX1-Evi-1 fusion gene inhibited differentiation and apoptosis in myelopoiesis: an in vivo study.
Shen L; Zhu J; Chen F; Lin W; Cai J; Zhong J; Zhong H
BMC Cancer; 2015 Dec; 15():970. PubMed ID: 26674644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
